SecBot SecBot
6-K ·Filed Apr 27, 2026

EVAX

Evaxion A/S
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001171843-26-002722
Notable filing: 6-K
Actionable Insight • Neutral

Monitor upcoming earnings or pipeline updates for signs of improved operational execution or partnership activity that may result from the leadership change. Absent financial or strategic catalysts, this promotion is a routine internal realignment with limited near-term trading implications.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.18
T+0 close · Apr 27, 2026 · via day close
Latest settled
−27.27%
T+60 · $3.04
Vs SPY
−32.05%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $4.18entry
  2. T+1 · 7mo ago +3.35%α +3.83% · $4.32
  3. T+5 · 7mo ago +9.33%α +8.93% · $4.57
  4. T+20 · 6mo ago −1.67%α −6.63% · $4.11
  5. T+60 · 4mo ago −27.27%α −32.05% · $3.04
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion A/S announced the promotion of Birgitte Rn from Chief Scientific Officer (CSO) to a dual role as CSO and Chief Operating Officer (COO), citing organizational alignment and her long-standing operational and scientific contributions. The move is intended to enhance external engagement and strategy execution around its AI-Immunology platform.

Key Facts

  • Birgitte Rn promoted from CSO to joint CSO and COO role at Evaxion A/S
  • Promotion follows internal management review aimed at improving external visibility and strategic execution
  • No changes to other executive roles; management team remains stable
  • No financial terms, compensation changes, or structural reorganization disclosed
  • Filing consists solely of a press release with no material financial or operational updates

Financial Impact

No immediate financial impact disclosed

operating_expensemanagement_compensation

Risk Factors

  • Expanded responsibilities without additional team changes could strain leadership capacity
  • Lack of external hires or structural changes may limit impact on investor engagement

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-002722
Exhibit: exh_991.htm0001171843-26-002722
Document: 0001171843-26-002722-index-headers.html0001171843-26-002722
Document: 0001171843-26-002722-index.html0001171843-26-002722
Document: 0001171843-26-002722.txt0001171843-26-002722

Track record

50 reports on EVAX

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026